Is the World Health Organization Hepatitis B Virus (HBV) DNA Standard Appropriate for Standardizing Serum HBV RNA Assays?

2020 ◽  
Author(s):  
Shi Liu ◽  
Rui Deng ◽  
Bin Zhou ◽  
Jian Sun
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
World Health Organization ◽  
Hbv Dna ◽  
World Health ◽  
B Virus ◽  
The World ◽  
Health Organization

scholarly journals Pharmacotherapeutic management of chronic viral hepatitis

2021 ◽  
Vol 2 (4) ◽  
pp. 1-8
Author(s):  
Gabriela Mitea ◽  
Marius Daniel Radu ◽  
Ana Maria Ionescu ◽  
Nicoleta Blebea
Keyword(s):  
Hepatitis B ◽  
Viral Hepatitis ◽  
World Health Organization ◽  
Geographical Area ◽  
Chronic Viral Hepatitis ◽  
World Health ◽  
Effective Vaccine ◽  
Special Importance ◽  
The World ◽  
Health Organization

In infectious diseases, viral hepatitis has an increased incidence, being an important cause of morbidity and mortality, being a "sentinel" indicator of the socio-economic and hygienic-cultural standard of a geographical area. The World Health Organization (WHO) admits the following types of hepatitis viruses: A, B, B + D, C, E, F and G. Among the viral entities recognized by the WHO, a special importance in terms of incidence, evolution over time with the risk of chronicity and the therapeutic options are presented by hepatitis B and C. There is currently an effective vaccine as well as treatment for hepatitis B. There is no vaccine for hepatitis C, but in recent years considerable progress has been made in treating this disease. Also, the introduction of drugs known as direct-acting antivirals makes it possible to cure over 90% of patients within 2-3 months. But in many countries, current drug policies, regulations and prices keep treatment out of the reach of most people with hepatitis. Eradication of viral hepatitis is possible if greater emphasis is placed on prevention, diagnosis and treatment. Vaccination is very important, as it is possible for types A and B of hepatitis. Early diagnosis is also extremely important, given that there are currently very effective drugs that can prevent the development of liver cancer. The WHO also noted that about two million people worldwide become ill each year due to the reuse of syringes and stressed the importance of checking blood donors to see if they are not carriers of hepatitis B or C viruses. Therefore, the purpose of this article is to highlight the pharmacological treatment and the main therapeutic and prevention schemes currently used for patients with these liver diseases. The paper was based on the most popular methods of identification of the latest international information about the treatment of hepatitis (by electronic search using Pubmed, SciFinder, Scirus, GoogleScholar and Web of Science). We also consulted the global literature cited in the hepatitis database of the World Health Organization (WHO) updated frequent from the current literature on this topic.

scholarly journals Occult hepatitis B virus infection among hemodialysis patients

2018 ◽  
Vol 91 (2) ◽  
Author(s):  
Rahil Nahid Samiei ◽  
Somayeh Shokri ◽  
Shahab Mahmoudvand ◽  
Manoochehr Makvandi ◽  
Heshmatollah Shahbazian ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hbv Dna ◽  
Enzyme Linked Immunosorbent Assay ◽  
Hepatitis B Infection ◽  
Nested Polymerase Chain Reaction ◽  
Occult Hepatitis ◽  
B Virus ◽  
The World ◽  
Occult Hepatitis B

Hepatitis B virus is a major public health impasse all over the world. Recently a new form of hepatitis B infection named Occult hepatitis B Infection (OBI) has appeared globally. The OBI is defined as the presence of HBV DNA in the liver and/or blood in the absence of detectable serum HBsAg with/without anti-HBc or anti-HBs. The prevalence of OBI has been reported in hemodialysis (HD) patients in different regions of the world. Thus, this study investigated the prevalence of OBI among HD patients. The cross-sectional study was carried out on 84 HD patients. These sera were checked for HBsAg, HBc-IgG assessment using Enzyme linked immunosorbent assay. The DNA was extracted from the sera samples and tested for HBVDNA detection using Nested Polymerase Chain Reaction (Nested PCR). The liver function tests including serum alanine aminotransferase and aspartate aminotransferase levels were carried out for all the HD individuals. 52/84(61.9%) of HD were males and 32/84 (38.1%) were females. The patient’s age ranged from 25 to 64 with a mean age of 52.4±15.2 years. HBsAg and HBc-IgG were detected in 1(1.1%) female. 2 (2.4%; a female and a male) patients were positive for HBsAg. 14/84 (16.7%; 6 female and 8 male) HD patients were positive for anti-HBc but negative for HBsAg, among them 4(28.6%; 2 female and 2 male) cases were positive for HBV DNA, indicating the presence of OBI in HD patients. Even distribution of OBI among the HD was found in 2(2.36%) male and 2(2.36%) female (P>.0.05). In the present study the moderate rate of 4.76% OBI has been observed in HD patients. The prevalence of seropositive OBI among the gender was 2(2.36%) male and 2(2.36%) female. The seronegative OBI have not been detected in the present study but requires further investigation. In this study the affliction of OBI in HD patients is not clear.

Hepatitis B control among children in the Eastern Mediterranean Region of the World Health Organization

Vaccine ◽  
2016 ◽  
Vol 34 (21) ◽  
pp. 2403-2409 ◽  
Author(s):  
Robert D. Allison ◽  
Nadia Teleb ◽  
Salah Al Awaidy ◽  
Hossam Ashmony ◽  
James P. Alexander ◽  
...  
Keyword(s):  
Hepatitis B ◽  
World Health Organization ◽  
Mediterranean Region ◽  
Eastern Mediterranean ◽  
Eastern Mediterranean Region ◽  
World Health ◽  
The World ◽  
Health Organization

scholarly journals Is it Safe for a Mother Infected with Hepatitis B Virus to Breastfeed Her Baby?

2012 ◽  
Vol 35 (1) ◽  
pp. 20-25
Author(s):  
ASM Nawshad Uddin Ahmed ◽  
Md Mahbubul Hoque
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Perinatal Transmission ◽  
Hepatitis B Vaccine ◽  
Hbv Infection ◽  
World Health ◽  
Increased Risk ◽  
Major Mode ◽  
B Virus ◽  
The World

One third of the world’s population has been infected by the hepatitis B virus (HBV), causing an enormous burden of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hepatitis B virus is transmitted through contact with blood and blood products, by sexual contact, through close contact between children (horizontal transmission), or by perinatal transmission from a carrier mother to her baby. In Asia, perinatal transmission is the major mode of transmission and those who become infected perinatally with HBV are most likely to develop chronic infection. The question of whether breastfeeding by HBV-positive mothers is an additional mechanism by which infants may acquire HBV infection, has been asked for many years. Although small amounts of hepatitis B surface antigen (HBsAg) have been detected in some samples of breast milk, there is no evidence that breastfeeding by HBV-carrier mothers increase the risk of mother-to-child transmission of HBV. Infants born to known hepatitis B positive women should receive hepatitis B immune globulin (HBIG) and hepatitis B vaccine, effectively eliminating any theoretical risk of transmission through breastfeeding. However, neither screening of pregnant women for HBV infection nor use of HBIG is feasible in most developing countries. Routine immunization of infants with hepatitis B vaccine is therefore recommended by the World Health Organization. Bangladesh has already included hepatitis B vaccine as part of routine childhood immunization in EPI program since 2003. Also the risk must be balanced against the increased risk of morbidity and mortality due to malnutrition and diarrheal or other infectious diseases associated with replacement feeding. Malnutrition is responsible, directly or indirectly, for 6.5 million under 5 deaths annually. Thus, even where HBV infection is highly endemic and immunization against HBV is not available, breastfeeding remains the recommended method of feeding. DOI: http://dx.doi.org/10.3329/bjch.v35i1.10369 BJCH 2011; 35(1): 20-25

scholarly journals Hepatitis B Virus Elimination in the U.S.: Time to Dismantle Barriers and Implement Solutions

2021 ◽  
Author(s):  
Su Wang ◽  
Chari Cohen ◽  
Amy S. Tang ◽  
Camilla S. Graham
Keyword(s):  
Public Health ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Scale Up ◽  
World Health ◽  
Public Health Services ◽  
Virus Elimination ◽  
B Virus ◽  
Health Organization ◽  
The U.S

Abstract Purpose of Review The World Health Organization has set a target for the elimination of hepatitis B virus (HBV) infection as a public health threat by 2030, but the U.S. is not currently on track. In this review, we describe specific barriers to HBV elimination, provide examples of potential solutions, and offer recommendations for how the U.S. can reach HBV elimination goals. Recent Findings In the U.S., there are many barriers to eliminating hepatitis B, worsened by the siloing of healthcare and public health services. In recent years, we have not seen progress toward improving HBV screening or adult vaccination, and acute cases are on the rise. Current policies, guidelines, and recommendations can hinder elimination progress. Summary Simple policy and guideline changes will allow us to decentralize and scale-up hepatitis B screening, vaccination, and care. Dismantling current barriers will be critical to eliminating hepatitis B in the U.S.

scholarly journals Epigenetic heterogeneity after de novo assembly of native full-length Hepatitis B Virus genomes

2020 ◽  
Author(s):  
Chloe Goldsmith ◽  
Damien Cohen ◽  
Anaëlle Dubois ◽  
Maria-Guadalupe Martinez ◽  
Kilian Petitjean ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
De Novo ◽  
Expression Patterns ◽  
Cellular Transformation ◽  
Hbv Dna ◽  
World Health ◽  
Nanopore Sequencing ◽  
Increased Risk ◽  
B Virus

AbstractHepatitis B Virus (HBV) is a 3.2KB DNA virus that causes acute and chronic hepatitis. HBV infection is a world health problem, with 350 million chronically infected people at increased risk of developing liver disease and hepatocellular carcinoma (HCC). Methylation of HBV DNA in a CpG context (5mCpG) can alter the expression patterns of viral genes related to infection and cellular transformation. Moreover, it may also provide clues to why certain infections are cleared, or persist with or without progression to cancer. The detection of 5mCpG often requires techniques that damage DNA or introduce bias through a myriad of limitations. Therefore, we developed a method for the detection of 5mCpG on the HBV genome that does not rely on bisulfite conversion or PCR. With cas9 guided RNPs to specifically target the HBV genome, we enriched in HBV DNA from Primary Human Hepatocytes (PHH) infected with different HBV genotypes, as well as enriching in HBV from infected patient liver tissue; followed by sequencing with Oxford Nanopore Technologies MinION. Detection of 5mCpG by Nanopore sequencing was benchmarked with Bisulfite-quantitative Methyl Specific PCR (BS-qMSP). 5mCpG levels in HBV determined by BS-qMSP and Nanopore sequencing were highly correlated. Our Nanopore sequencing approach achieved a coverage of ∼2000x of HBV depending on infection efficacy, sufficient coverage to perform a de novo assembly and detect small fluctuations in HBV methylation, providing the first de novo assembly of native HBV DNA, as well as the first landscape of 5mCpG from native HBV sequences. Moreover, by capturing entire HBV genomes, we explored the epigenetic heterogeneity of HBV in infected patients and identified 4 epigenetically distinct clusters based on methylation profiles. This method is a novel approach that enables the enrichment of viral DNA in a mixture of nucleic acid material from different species and will serve as a valuable tool for infectious disease monitoring.

Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen

Blood ◽  
2002 ◽  
Vol 100 (7) ◽  
pp. 2637-2641 ◽  
Author(s):  
Holger Hennig ◽  
Ines Puchta ◽  
Jürgen Luhm ◽  
Peter Schlenke ◽  
Siegfried Goerg ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Blood Donors ◽  
Hbv Dna ◽  
World Health ◽  
Core Antigen ◽  
Enzyme Linked Immunosorbent Assay ◽  
Blood Donations ◽  
B Virus ◽  
First Time

The objective of this study was to determine the frequency and load of hepatitis B virus (HBV) DNA in anti-HBc–positive first-time blood donors; it was designed to contribute to determining whether anti-HBc screening of blood donations might reduce the residual risk of posttransfusion HBV infection. A total of 14 251 first-time blood donors were tested for anti-HBc using a microparticle enzyme immunoassay; positive results were confirmed by a second enzyme-linked immunosorbent assay (ELISA). For the detection of HBV DNA from plasma samples, we developed a novel and highly sensitive real-time polymerase chain reaction (PCR) assay. The 95% detection limit of the method amounted to 27.8 IU/mL, consistent with the World Health Organization (WHO) international standard for HBV DNA. A total of 216 blood donors (1.52%) tested anti-HBc–positive in both tests, and 205 of them (16 HBsAg+, 189 HBsAg−) were tested for HBV DNA. In 14 (87.5%) of the HBsAg-positive blood donors, HBV DNA was repeatedly detected, and in 3 (1.59%) of the HBsAg-negative donors, HBV DNA was also found repeatedly. In the 3 HBV DNA–positive, HBsAg-negative cases, anti-HBe and anti-HBs (> 100 IU/L) were also detectable. HBV DNA in HBsAg-negative as well as HBsAg-positive samples was seen at a low level. Thus, HBV DNA is sometimes found in HBsAg-negative, anti-HBc–positive, and anti-HBs–positive donors. Retrospective studies on regular blood donors and recipients are necessary to determine the infection rate due to those donations. Routine anti-HBc screening of blood donations could probably prevent some transfusion-transmitted HBV infections.

Sign in / Sign up

Export Citation Format

Share Document